Dysmenorrhea. How to improve the quality of life?
DOI: 10.32364/2618-8430-2021-4-1-46-52
A.A. Olina1,2, T.A. Meteleva3
1I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation
2D.O. Ott Research Institute of Obstetrics, Gynecology, & Reproduction, St. Petersburg, Russian Federation
3Academician E.A. Vagner Perm State Medical University, Perm, Russian Federation
Aim: to evaluate the rate of dysmenorrhea among secondary and high school students and to validate a differentiated treatment approach to hormonal contraception.
Patients and Methods: 1,435 secondary and high school students of the city of Perm aged 18–25 years were interviewed over a 4-month period. 223 girls who complained of painful periods were examined (anthropometry, pain assessment using a visual analogous scale/VAS, and pelvic ultrasound). In addition, the rate of dysmenorrhea was assessed using the statistical form No. 12 “Data on the number of cases registered in the patients who are resident in the territory serviced by a medical organization”.
Results: according to official statistics, the rate of menstrual disorders (including dysmenorrhea) is 0.70–2.03%. The survey has demonstrated that 84.1% of students experience period pain. However, only 18.4% of them see a gynecologist. 63.2% experience pain for 2–3 days, 34% describe their pain as severe (VAS 7–10), and 29.1% are forced to take three or more NSAID pills daily. The symptoms of endometriosis were revealed in every tenth girl. A personalized choice of hormonal contraception allowed for the reduction in pain severity (none of the girls reported on severe pain, i.e., VAS 7–10), period duration, and heavy periods.
Conclusions: official statistics does not illustrate the actual prevalence of dysmenorrhea. A personalized choice of hormonal contraception provides high compliance rate, the required duration of treatment, pain relief, the improvement of neuro-vegetative and metabolic processes and, as a result, a significant improvement in the quality of life.
Keywords: dysmenorrhea, hormonal contraception, endometriosis, chronic pelvic pain, quality of life, drospirenone.
For citation: Olina A.A., Meteleva T.A. Dysmenorrhea. How to improve the quality of life? Russian Journal of Woman and Child Health. 2021;4(1):46–52. DOI: 10.32364/2618-8430-2021-4-1-46-52.
2. Sinchihin S.P., Mamiev O.B., Suverneva A.A., Kakurin V.I. Dysmenorrhoea — modern attitude to etiology, pathogenesis, diagnostics, clinic and treatment (literature review). Astrakhanskiy meditsinskiy zhurnal. 2010;5(1):35–43 (in Russ.).
3. De Sanctis V., Soliman A., Bernasconi S. et al. Primary dysmenorrhea in adolescents: prevalence, impact and recent knowledge. Pediatr Endocrinol Rev. 2015;13(2):512–520.
4. Iacovides S., Avidon I., Baker F.C. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015;21(6):762–778. DOI: 10.1093/humupd/dmv039.
5. Osayande A.S., Mehulic S. Diagnosis and initial management of dysmenorrhea. Am Fam Physician. 2014;89(5):341–346.
6. Trushkevich A.A., Mysenko A.D. Optimization of methods for early diagnosis of endometriosis in risk groups — patients of early reproductive age with dysmenorrhea. Nauchnyy rukovoditel’. 2014;3(4):102–114 (in Russ.).
7. Order of the Ministry of Health of the Russian Federation dated 01.11.2012 No. 572n (as amended by orders of the Ministry of Health of Russia dated 17.01.2014 No. 25n, dated 11.06.2015 No. 333n, dated 12.01.2016 No. 5n) “On approval of the procedure for the provision of medical care in the field of obstetrics and gynecology (excluding the use of assisted reproductive technologies)” (in Russ.).
8. Jing Xie, Kvaskoff M., Li Y et al. Severe teenage acne and risk of endometriosis. Hum Reprod. 2014;29(11):2592–2599. DOI: 10.1093/humrep/deu207.
9. Yeung Jr.P., Gupta S., Gieg S. Endometriosis in adolescents: a systematic review. J Endometr Pelv Pain Disord. 2017;9(1):17–29. DOI: 10.5301/je.5000264.
10. Matalliotakis M., Goulielmos G.N., Matalliotakiet C. et al. Endometriosis in adolescent and young girls: report on a series of 55 cases. J Pediatr Adolesc Gynecol. 2017;30(5):568–570. DOI: 10.1016/j.jpag.2017.05.007.
11. Unanyan A.L., Sidorova I.S., Sosnova E.A. et al. Dysmenorrhea, adenomyosis, endometriosis, tumor process: causation. Meditsinskiy sovet. 2017;11:186–188 (in Russ.).
12. Levakov S.A., Khamoshina M.B. Endometriosis: a worldwide breakthrough in medical treatment. M.: StatusPraesens; 2012 (in Russ.).
13. Brosens I., Puttemans P., Benagiano G. Endometriosis: a life cycle approach? Am J Obstet Gynecol. 2013;209(4):307–316. DOI: 10.1016/j.ajog.2013.03.009.
14. Harada T., Khine Y.M., Kaponis A. et al. The impact of adenomyosis on women’ fertility. Obstet Gynecol Surv 2016;71(9):557–568. DOI: 10.1097/OGX.0000000000000346.
15. Endometriosis. Clinical guidelines. M.; 2020 (in Russ.).
16. Smorgick N., Marsh C.A., As-Sanie S. et al. Prevalence of pain syndromes, mood conditions, and asthma in adolescents and young women with endometriosis. J Pediatr Adolesc Gynecol. 2013;26(3):171–175. DOI: 10.1016/j.jpag.2012.12.006.
17. Tølbøll Glavind M., Forman A., Håkonsen Arendt L. et al. Endometriosis and pregnancy: a Danish cohort study. Fertil Steril. 2016;109(1):160–166. DOI: 10.1016/j.fertnstert.2016.09.020.
18. Carrarelli P., Lunardi Rocha A.L., Belmonte G. et al. Increased expression of antimüllerian hormone and its receptor in endometriosis. Fertil Steril. 2014;101(5):1353–1358. DOI: 10.1016/j.fertnstert.2014.01.052.
19. Pattanittum P., Kunyanone N., Brown J. et al. Dietary supplements for dysmenorrhoea. Cochrane Database Syst Rev. 2016;3(3):CD002124. DOI: 10.1002/14651858.CD002124.pub2.
20. Medical eligibility criteria for contraceptive use. WHO, 2009. 4th ed. М.; 2012 (in Russ.).
21. Medical eligibility criteria for contraceptive use. WHO, 2015. 5th ed. Geneva; 2015 (in Russ.).
22. Kuznetsova I.V., Khovrina E.A., Kirpikov A.S. Seriously and for a long time the possibility of using COCs for genital endometriosis. StatusPraesens. Gynecology, obstetrics, barren marriage. 2012;4(10):36–40 (in Russ.).
23. Tu F.F., Du H., Goldstein G.P. et al. The influence of prior oral contraceptive use on risk of endometriosis is conditional on parity. Fertil Steril. 2014;101(6):1697–1704. DOI: 10.1016/j.fertnstert.2014.02.014.
24. Vercellini P., Buggio.L, Berlanda N. et al. Estrogen-progestins and progestins for the management of endometriosis. Fertil Steril. 2016;106(7):1552–1571. DOI: 10.1016/j.fertnstert.2016.10.022.
25. Kitajima M., Dolmans M.-M., Donnez O. et al. Enhanced follicular recruitment and atresia in cortex derived from ovaries with endometriomas. Fertil Steril. 2014;101(4):1031–1037. DOI: 10.1016/j.fertnstert.2013.12.049.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
